Bone Biologics reported raising $729,000 in an initial SEC Form D filing, from an offering of $729,000
PUBLIC · BBLGNov 29, 2023
Amount Raised
$729,000
$729,000 sold, per SEC Form D (first sale Nov 16, 2023)
Round Type
Seed
BurlingtonBiotechnology
Quick answer
Bone Biologics raised $729,000 in a Seed round, dated November 16, 2023. Bone Biologics is based in Burlington, Massachusetts, United States.
How much did Bone Biologics raise?
Bone Biologics raised $729,000 in a Seed round on November 16, 2023.
What does Bone Biologics do?
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA.
Where is Bone Biologics based and how big is it?
Bone Biologics is based in Burlington, Massachusetts, United States. Fundz records about 2 employees.
Who are the decision-makers at Bone Biologics?
Fundz holds 1 contact at Bone Biologics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Bone Biologics that raised within 45 days of this round, from Fundz verified event records.
Sanuwave raised $1.9M (Seed) on December 30, 2023.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Bone Biologics
Location
2 BURLINGTON WOODS DRIVE
Burlington, Massachusetts, United States
About
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka University professor and a USC surgeon and acquired in 2006 by MTF as the major shareholder, who has been the primary funder since the acquisition. The Company’s proprietary, patented platform technology UCB-1™, exclusively licensed from UCLA, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and Rhesus Monkey) studies that have demonstrated that the UCB-1™ technology facilitates superior normal bone growth. The company believes that as a platform technology, UCB-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.
Bone Biologics lead product is focused on bone regeneration in human lumbar spinal fusion using our recombinant human protein growth factor, known as Nell-1. Nell-1 is currently under development and progressing toward near term clinical trial studies in human lumbar fusion because Bone Biologics believes that lumbar surgeons are currently underserved by suitable quality outcome results and are receptive to new biological therapies that are target specific.
Our mission is to utilize the power of Nell-1 to improve clinical outcomes and reduce total health care delivery costs associated with lumbar spinal fusion. The company is focused on bone repair and regeneration applications and is committed to exploring additional applications of the UCB-1™ technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bone Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BurlingtonBiotechnology